Becton, Dickinson and Company: Business Overview, Financials & Competitive Analysis
Becton, Dickinson and Company scores 6/10 on the AskCyborg Cyborg Score (Solid). Diversified medical technology leader navigating post-restructuring with solid profitability but near-term margin pressure from tariffs. The company beat earnings expectations with strong Q1 2026 results and reaffirmed guidance for ~6% EPS growth at midpoint. However, adjusted gross margin declined 140 basis points due to tariffs, and adjusted operating.
What is Becton, Dickinson and Company's industry? Becton, Dickinson and Company (bd.com) operates in Medical Technology & Devices. AskCyborg classifies Becton, Dickinson and Company under Medical Technology & Devices in its company registry.
Becton, Dickinson and Company (NYSE: BDX) is a leading global medical technology company. Following a reorganization effective October 1, 2025, the company operates through five segments: Medical Essentials, Connected...
Cyborg Score thesis
Diversified medical technology leader navigating post-restructuring with solid profitability but near-term margin pressure from...
Read the full analyst-debate transcript →Get the Latest Becton, Dickinson and Company Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeBecton, Dickinson and Company Overview
Pro stress-test →Becton, Dickinson and Company (NYSE: BDX) is a leading global medical technology company. Following a reorganization effective October 1, 2025, the company operates through five segments: Medical Essentials, Connected Care, Biopharma Systems, Interventional, and Life Sciences (Biosciences Diagnostic Solutions). BDX recently completed the spin-off of its Life Sciences & Diagnostic Solutions segment, receiving $4B to be split between debt reduction and share repurchases.
Strategic Profile
Pro stress-test →Becton, Dickinson and Company delivered a Q1 2026 earnings beat, with $2.91 non-GAAP EPS and $5.25B revenue, surpassing expectations. New Becton, Dickinson and Company grew 2.5%, with broad-based growth across the markets where the company has been doubling down on investments. For fiscal 2026, the company continues to expect new Becton, Dickinson and Company to deliver low single-digit revenue growth.
Competitive Landscape
Pro stress-test →Becton Dickinson competes in the global medical technology sector against established diversified healthcare companies. Primary competitors include companies like Medtronic and Abbott Laboratories in various medical device segments, alongside specialized players in diagnostics and drug delivery systems. BD maintains competitive positioning through innovation in pharmacy automation, biologic drug delivery systems, and diagnostic solutions.
Industry Context
Becton, Dickinson and Company operates in Medical Technology & Devices.
Key facts
Founded: 1897 · Headquarters: Franklin Lakes, New Jersey · Employees: ~85,000 · Revenue: $5.25B (Q1 FY2026) · Market cap: ~$88B